AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Neogen Corp
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S67B47
12.19▲ 0.21 (1.75%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
11.98
Day's Range
11.82 – 12.34
52-Week Range
5.37 – 14.26
Volume
2.7M
Avg Volume
4.6M
Share Statistics
Shares Outstanding
Employees
1,456
Exchange
XNAS
Listed
1989-08-23
Share count as of August 31, 2026

Neogen Corp (NEOG) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Neogen Corp (NEOG)
What is Neogen Corp's Market Cap?
Neogen Corp's Market Cap is $2.7B, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's Enterprise Value?
Neogen Corp's Enterprise Value is $4.0B, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's Price / Sales?
Neogen Corp's Price / Sales is 3.0×, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's EV / Revenue?
Neogen Corp's EV / Revenue is 4.6×, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's EV / EBITDA?
Neogen Corp's EV / EBITDA is 37.1×, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's Revenue (TTM)?
Neogen Corp's Revenue (TTM) is $884.0M, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's Net Income (TTM)?
Neogen Corp's Net Income (TTM) is -$56.1M, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's EBITDA?
Neogen Corp's EBITDA is $109.0M, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's Diluted EPS (TTM)?
Neogen Corp's Diluted EPS (TTM) is -0.26, based on as-reported figures from SEC (XBRL) filings.
What is Neogen Corp's EBITDA Margin?
Neogen Corp's EBITDA Margin is 12.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NEOGAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemAug 31, 2026May 31, 2026Feb 28, 2026Nov 30, 2025Aug 31, 2025May 31, 2025Feb 28, 2025Nov 30, 2024Aug 31, 2024May 31, 2024Feb 29, 2024Nov 30, 2023Aug 31, 2023May 31, 2023Feb 28, 2023Nov 30, 2022
Revenues
Total Revenues
YoY growth+6.5%-0.1%-4.4%-2.8%
Cost of Revenues
Total Cost of Revenues
Gross Profit
% of revenue47.4%47.8%46.9%47.5%
Operating Expenses
Sales and marketing
General and administrative
Goodwill impairment—
Research and development
Total Operating Expenses
% of revenue48.2%46.5%48.4%49.9%
Operating Loss
% of revenue-0.8%1.4%-1.6%-2.4%
Other (Expense) Income
Interest expense, net
(Loss) Gain on sale of business
Other, net
Total Other (Expense) Income
(Loss) Income Before Taxes
Income Tax (Benefit) Expense
Net (Loss) Income
% of revenue-5.3%-5.0%-8.0%-7.1%
Net (Loss) Income Per Share
Basic
Diluted